These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 38944271)
1. Perioperative outcomes and survival after neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma. Yang X; Yin H; Zhang S; Jiang T; Gu J; Jiao H; Wang H; Liang F; Xu S; Fan H; Ding J; Ge D; Wang Q; Yin J; Tan L J Thorac Cardiovasc Surg; 2025 Jan; 169(1):289-300.e6. PubMed ID: 38944271 [TBL] [Abstract][Full Text] [Related]
2. Mid-term follow-up results of neoadjuvant sintilimab combined with chemotherapy for locally advanced resectable esophageal squamous cell carcinoma. Cai H; Chen L; Huang J; Ma H; Zhang S; Zhong K; Yang D; Sun J; Liu H; Song R Front Immunol; 2024; 15():1453176. PubMed ID: 39697347 [TBL] [Abstract][Full Text] [Related]
3. [Neoadjuvant chemoradiotherapy versus neoadjuvant chemo-immunotherapy for locally advanced esophageal squamous cell carcinoma]. Wang XY; Shen HX; Li RH; Wang JF; Fang M; Tao KY; Jiang YH; Ji YL Zhonghua Zhong Liu Za Zhi; 2024 Nov; 46(11):1058-1066. PubMed ID: 39622738 [No Abstract] [Full Text] [Related]
4. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery. Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421 [TBL] [Abstract][Full Text] [Related]
5. Survival comparison between open and thoracoscopic esophagectomy for node-negative esophageal squamous cell cancer: an ambispective cohort study. Jia X; Ren T; Chen P; Xin X; Zhang Y; Yang Y Surg Endosc; 2024 Dec; 38(12):7341-7351. PubMed ID: 39433581 [TBL] [Abstract][Full Text] [Related]
6. Comparison of efficacy and safety of neoadjuvant immunochemotherapy in young and elderly patients with IIA-IIIB non-small-cell lung cancer in real-world practice. Liu J; Huang X; Yang Y; Lv W; Wang Y; Xia P; Hu J BMC Pulm Med; 2024 Nov; 24(1):592. PubMed ID: 39614293 [TBL] [Abstract][Full Text] [Related]
7. Postoperative tumor bed radiation versus T-shaped field radiation in the treatment of locally advanced thoracic esophageal squamous cell carcinoma: a phase IIb multicenter randomized controlled trial. Zeng Y; Li J; Ye J; Han G; Luo W; Wu C; Qin S; Gu W; Zhao S; Zhao Y; Xia B; Zhu Z; Du X; Liu Y; Liu J; Li H; Wang J; Guo J; Yu W; Zhang Q; Wang C; Fang W; Li Z; Fu X; Cai X BMC Med; 2024 Nov; 22(1):522. PubMed ID: 39511550 [TBL] [Abstract][Full Text] [Related]
8. Comparison of proton-based definitive chemoradiotherapy and surgery-based therapy for esophageal squamous cell carcinoma: a multi-center retrospective Japanese cohort study. Ogawa K; Ishikawa H; Toyozumi T; Noma K; Kono K; Hojo H; Tamamura H; Azami Y; Ishida T; Nabeya Y; Iwata H; Araya M; Tokumaru S; Maruo K; Oda T; Matsubara H Esophagus; 2024 Oct; 21(4):484-494. PubMed ID: 38844703 [TBL] [Abstract][Full Text] [Related]
9. Evaluating the Impact of Age and G8 Assessment on Definitive Treatment Strategies in Elderly Patients with Local Advanced Esophageal Carcinoma. Akkus Yildirim B; Gokhan Acikgoz S; Akboru MH; Uysal E; Tütün B; Gurdal N; Tezcan Y Oncol Res Treat; 2024; 47(12):590-601. PubMed ID: 39413748 [TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial. Liu SL; Li XY; Yang JH; Wen DX; Guo SS; Liu LT; Li YF; Luo MJ; Xie SY; Liang YJ; Sun XS; Yang ZC; Lv XF; Luo DH; Li JB; Liu Q; Wang P; Guo L; Mo HY; Sun R; Yang Q; Lan KQ; Jia GD; Li R; Zhao C; Xu RH; Chen QY; Tang LQ; Mai HQ Lancet Oncol; 2024 Dec; 25(12):1563-1575. PubMed ID: 39522541 [TBL] [Abstract][Full Text] [Related]
11. Patients with complete clinical response after neoadjuvant chemoradiotherapy for locally advanced esophageal cancer: A Markov decision analysis of esophagectomy versus active surveillance. Bondzi-Simpson A; Ribeiro T; Grant A; Ko M; Coburn N; Hallet J; Kulkarni GS; Kidane B J Thorac Cardiovasc Surg; 2024 Dec; 168(6):1538-1549.e1. PubMed ID: 38649112 [TBL] [Abstract][Full Text] [Related]
12. Prognostic Impact of Inflammation-Based Factors in Patients with Esophageal Squamous Cell Carcinoma Achieving Pathological Complete Response After Neoadjuvant Chemoradiotherapy Followed by Surgery. Kim JY; Yun JK; Kim YH; Park SI; Lee JH; Jung HY; Lee GH; Song HJ; Kim DH; Choi KD; Ahn JY; Kim SB; Cho KJ; Ryu JS; Kim JH; Kang J; Park SR; Kim HR Ann Surg Oncol; 2024 Oct; 31(10):6662-6672. PubMed ID: 38954089 [TBL] [Abstract][Full Text] [Related]
14. Perioperative tislelizumab with four cycles of neoadjuvant chemotherapy for resectable locally advanced esophageal squamous cell carcinoma: a phase 2 study. Zhou N; Hua Y; Ge Y; Wang Q; Wang C; He J; Zhao L; Yu S; Yan J; Zhao L; Li L; Bai C Front Immunol; 2024; 15():1482005. PubMed ID: 39687611 [TBL] [Abstract][Full Text] [Related]
15. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Morgan RD; McNeish IA; Cook AD; James EC; Lord R; Dark G; Glasspool RM; Krell J; Parkinson C; Poole CJ; Hall M; Gallardo-Rincón D; Lockley M; Essapen S; Summers J; Anand A; Zachariah A; Williams S; Jones R; Scatchard K; Walther A; Kim JW; Sundar S; Jayson GC; Ledermann JA; Clamp AR Lancet Oncol; 2021 Feb; 22(2):277-288. PubMed ID: 33357510 [TBL] [Abstract][Full Text] [Related]
16. Local excision for middle-low rectal cancer after neoadjuvant chemoradiation: A retrospective study from a single tertiary center. Chen N; Li CL; Wang L; Yao YF; Peng YF; Zhan TC; Zhao J; Wu AW World J Gastrointest Oncol; 2024 Dec; 16(12):4614-4624. PubMed ID: 39678786 [TBL] [Abstract][Full Text] [Related]
17. Prognostic Effect of the PNI and LSR in Patients with Esophageal Squamous Cell Carcinoma Patients Receiving Radiotherapy. Gao J; Li M; Wang Y; Wang Z; Chen X; Li H J Gastrointest Cancer; 2024 Nov; 56(1):26. PubMed ID: 39601941 [TBL] [Abstract][Full Text] [Related]
18. Definitive chemoradiotherapy with paclitaxel for locally advanced esophageal squamous cell carcinoma in older patients (PARADISE-1): a phase I trial. Hirata K; Yoshida K; Katada C; Watanabe A; Tsushima T; Yamaguchi T; Yamamoto S; Ishikawa H; Sato Y; Imamura CK; Tanigawara Y; Ito Y; Kato K; Kitagawa Y; Hamamoto Y BMC Cancer; 2024 Jul; 24(1):873. PubMed ID: 39030570 [TBL] [Abstract][Full Text] [Related]
19. CT-based delta-radiomics for predicting pathological response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma: a multicenter study. Zheng Y; Mei P; Wang M; Luo Q; Li H; Ding C; Zhang K; Chen L; Gu J; Li Y; Guo T; Zhang C; Yao W; Wei L; Liao Y; Han X; Shi H BMC Med Imaging; 2024 Dec; 24(1):329. PubMed ID: 39627736 [TBL] [Abstract][Full Text] [Related]
20. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone. Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]